HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
Paul G. Richardson(Harvard University), María‐Victoria Mateos(Hospital Clínico San Carlos), Alessandra Larocca(Cornell University), Agne Paner(Rush University Medical Center), Joan Bladé(Hospital Clínic de Barcelona), Adrían Alegre(Hospital Universitario de La Princesa), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute), Johan Harmenberg(Oncopeptides (Sweden)), Noemí Puig(Instituto de Investigación Biomédica de Salamanca), Xavier Leleu(Inserm), Albert Oriol(Institut Català d'Oncologia), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Michèle Cavo(Unknown), John Harran(Harvard University), Sara Thuresson(Oncopeptides (Sweden)), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Hanan Zubair(Oncopeptides (Sweden)), Christopher Maisel(Baylor Medical Center at Garland), Amitabha Mazumder(NYU Langone Health), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 2
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k